SureWerx® Acquires Genesi S.r.l.
26.6.2026 10:00:00 CEST | Business Wire | Press release
Expanding SureWerx’s Global Portfolio with Leading Work-at-Height and Confined Space Safety Solutions
SureWerx®, a leading global provider of safety, tool & equipment products, announced today that it has acquired Genesi S.r.l. Terms were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626881708/en/
Based in Bergamo, Italy, Genesi is a leading provider of safety solutions for work-at-height and confined space solutions. For more than 20 years, Genesi has built its reputation on a customer-centered approach, combining innovative, high-quality products with engineering expertise, training, services, maintenance and after-sales support to help protect workers in high-risk environments. Its portfolio includes fall protection systems, horizontal and vertical lifelines, anchor points, guardrails, ladders, access solutions, and confined space safety systems. Guided by the belief that there is no protection without knowledge, Genesi is committed to advancing safety culture and helping workers return home safely every day.
This acquisition further strengthens SureWerx’s fall protection platform and enhances its ability to deliver integrated work-at-height and confined space safety solutions to customers across Europe and North America.
“We are excited to welcome Genesi S.r.l. to SureWerx — a strong strategic addition that expands our work-at-height, confined space and rescue solutions for customers in Europe and soon, North America,” said Scott Dowell, CEO of SureWerx. “Genesi brings market-leading expertise in confined space entry, rescue and fall protection systems. Together with Fall Safe’s trusted portfolio of harnesses, SRLs, lanyards, and anchors, this acquisition strengthens our ability to deliver a more complete, integrated range of high-performance fall protection solutions across multiple segments and geographies.”
“Genesi's mission has always been clear: to design and produce state-of-the-art fall arrest systems, complementing them with excellent training through the Genesi Academy,” said Simone Cornali, founder of Genesi. “Our goal is to integrate products, services, and training to protect people's lives and spread the safety culture, so that every worker can return home safe and sound. We are excited to partner with SureWerx, a company that shares our values and our commitment to protection at height and in confined spaces. SureWerx’s global reach, strong channel partnerships, and deep fall protection expertise will help accelerate Genesi’s growth in Europe and beyond while advancing our shared mission to make high-risk work safer.”
About SureWerx
Co-headquartered in Vancouver, Canada, and Elgin, Illinois, SureWerx is a leading global manufacturer of professional safety products, tools, and equipment. SureWerx markets its safety products under multiple brands, including Jackson Safety®, Sellstrom®, Pioneer®, PeakWorks®, ADA Solutions®, Armor Tile, Access Tile, Due North®, K1 Series®, Avenger, Nautilus®, MEGAComfort, NEOS®, Oberon, FALL SAFE®,and Reliance Fall Protection®.
SureWerx provides global access to its brands through a broad distributor network serving the industrial, construction, safety, electrical, utilities, resources, transportation, automotive aftermarket, and food production markets. For more information, visit www.surewerx.com.
About Genesi S.r.l.
Headquartered in Bergamo, Italy, and founded in June 2006, Genesi provides end-to-end safety solutions for work-at-height and confined space applications, including preliminary site analysis, customized system design, production, installation, maintenance, training, and after-sales support. Education and training are central to Genesi’s philosophy because there is no protection without knowledge. For more information, visit www.genesiprotection.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260626881708/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom